Polymer nanoparticles encapsulating siRNA for treatment of HSV-2 genital infection.

@article{Steinbach2012PolymerNE,
  title={Polymer nanoparticles encapsulating siRNA for treatment of HSV-2 genital infection.},
  author={Jill M. Steinbach and Caroline E. Weller and Carmen J. Booth and W. Mark Saltzman},
  journal={Journal of controlled release : official journal of the Controlled Release Society},
  year={2012},
  volume={162 1},
  pages={
          102-10
        }
}
Effective, low-cost, and safe treatments for sexually transmitted viral infections are urgently needed. Here, we show for the first time that intravaginal administration with nanoparticles of poly(lactic-co-glycolic acid) (PLGA) encapsulating short interfering RNA (siRNA) molecules is effective for prevention of genital HSV-2 infections in mice. PLGA nanoparticles (NPs) were designed to interfere with HSV-2 infection by siRNA-mediated knockdown of nectin, a host cell protein. NPs were… Expand
Vaginal siRNA delivery: overview on novel delivery approaches
TLDR
Various nanocarrier systems like lipid-based delivery systems, macromolecular systems, polymeric nanoparticles, aptamer and cell-penetrating peptides and their promising outcomes at preclinical stage are elaborated on. Expand
Biodegradable Film for the Targeted Delivery of siRNA-Loaded Nanoparticles to Vaginal Immune Cells.
TLDR
The novel siRNA-NP-Ab-loaded film was transparent, displayed suitable physicomechanical properties, and was noncytotoxic, suggesting it may be a promising platform for preventing HIV infection within the female genital tract. Expand
Delivery Strategies for Developing siRNA-Based Vaginal Microbicides
TLDR
This chapter presents the strategies that are being used to achieve RNAi-mediated gene-specific silencing must be accomplished while minimizing toxic bystander effects. Expand
Precise engineering of dapivirine-loaded nanoparticles for the development of anti-HIV vaginal microbicides.
TLDR
Overall, obtained dapivirine-loaded PLGA NPs possess interesting technological and biological features that may contribute to their use as novel safe and effective vaginal microbicides. Expand
Nanoparticle-Mediated Systemic Delivery of siRNA for Treatment of Cancers and Viral Infections
TLDR
This review summarizes the various nanoparticulate systems developed so far in the literature for systemic delivery of siRNA, which include silica and silicon-based nanoparticles, metal and metal oxides nanoparticle, carbon nanotubes, graphene, dendrimers, polymers, cyclodextrins, lipids, hydrogels, and semiconductor nanocrystals. Expand
Polymers in the Delivery of siRNA for the Treatment of Virus Infections
Viral diseases remain a major cause of death worldwide. Despite advances in vaccine and antiviral drug technology, each year over three million people die from a range of viral infections.Expand
Polymers in the Delivery of siRNA for the Treatment of Virus Infections
Viral diseases remain a major cause of death worldwide. Despite advances in vaccine and antiviral drug technology, each year over three million people die from a range of viral infections.Expand
Sustained-release Griffithsin nanoparticle-fiber composites against HIV-1 and HSV-2 infections.
TLDR
In parallel, histology and cytokine expression from murine reproductive tracts and vaginal lavages collected 24 and 72 h post-administration were similar to untreated mice, suggesting that NP-EF composites may be a promising and safe sustained-delivery platform to prevent HSV-2 infection. Expand
Advancements in the field of intravaginal siRNA delivery.
TLDR
This review will focus on the therapeutic potential of siRNA for the treatment and/or prevention of infectious diseases such as HIV, HPV, and HSV within the vaginal tract with formulation design parameters to improve siRNA stability and therapeutic efficacy. Expand
Antiretroviral Hydrophobic Core Graft-Copolymer Nanoparticles: The Effectiveness against Mutant HIV-1 Strains and in Vivo Distribution after Topical Application
TLDR
insoluble orthogonal inhibitors of HIV-1 life cycle may be formulated into the non-aggregating ultrasmall NP which are highly efficient against NNRTI-resistant HIV- 1 variant. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 36 REFERENCES
Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA
TLDR
This is the first report demonstrating that biodegradable polymer nanoparticles are effective delivery vehicles for siRNA in the vaginal mucosa, using nanoparticles composed entirely of FDA-approved materials. Expand
An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection
TLDR
It is shown that vaginal instillation of small interfering RNAs (siRNAs) targeting HSV-2 protects mice from lethal infection and suggests that siRNAs are attractive candidates for the active component of a microbicide designed to prevent viral infection or transmission. Expand
Durable protection from Herpes Simplex Virus-2 transmission following intravaginal application of siRNAs targeting both a viral and host gene.
TLDR
It is shown that cholesterol-conjugated (chol)-siRNAs without lipid silence gene expression in the vagina without causing inflammation or inducing interferons could provide sustained protection against viral transmission. Expand
Optimizing siRNA delivery to the genital mucosa.
TLDR
The utility of siRNAs as a microbicide, usually applied to the genital mucosa for preventing transmission of sexually transmitted diseases including HIV-1 and HSV-2, has been investigated and potential strategies for improving gene silencing are discussed. Expand
Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras.
TLDR
It is shown that CD4 aptamer-siRNA chimeras (CD4-AsiCs) specifically suppress gene expression in CD4⁺ T cells and macrophages in vitro, in polarized cervicovaginal tissue explants, and in the female genital tract of humanized mice, protecting against HIV vaginal transmission. Expand
Nanoparticles containing siRNA to silence CD4 and CCR5 reduce expression of these receptors and inhibit HIV-1 infection in human female reproductive tract tissue explants
TLDR
These findings support the therapeutic development of nanoparticles to deliver siRNA molecules to silence host cell receptors in the female reproductive tract as a novel microbicide to inhibit mucosal HIV-1 transmission. Expand
Engineering mucosal RNA interference in vivo.
TLDR
It is demonstrated that RNA interference can be used to manipulate mucosal gene expression in vivo and Liposomal siRNA formulations proved nontoxic, did not elicit a nonspecific interferon response, and provide a means for genetic engineering of mucosal surfaces in vivo. Expand
Novel approaches to vaginal delivery and safety of microbicides: biopharmaceuticals, nanoparticles, and vaccines.
TLDR
Screening of new microbicide candidates and formulation excipients may avoid past issues of enhancing HIV-1 transmission, and combining prevention modalities may be the most effective means of preventing STI transmission. Expand
Nanoparticle-based vaginal drug delivery systems for HIV prevention
TLDR
This review summarizes nanoparticulate systems and their use in mucosal delivery to date as well as the potential opportunities, challenges and advantages in using a nanoparticle-based approach for microbicidal drug delivery. Expand
Several serum proteins significantly decrease inflammatory response to lipid-based non-viral vectors.
TLDR
It is suggested that a combination of protein content and DNA placement within the structure is responsible for the significantly improved efficacy and decreased inflammatory toxicity of these modified non-viral vectors. Expand
...
1
2
3
4
...